Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Endo International plc
IndexS&P 500 P/E- EPS (ttm)-5.32 Insider Own0.60% Shs Outstand177.89M Perf Week-1.19%
Market Cap16.60B Forward P/E18.31 EPS next Y5.10 Insider Trans0.00% Shs Float174.26M Perf Month1.74%
Income-727.00M PEG- EPS next Q1.04 Inst Own96.20% Short Float5.87% Perf Quarter19.54%
Sales2.88B P/S5.77 EPS this Y-4.70% Inst Trans0.27% Short Ratio3.29 Perf Half Y55.08%
Book/sh15.44 P/B6.05 EPS next Y14.41% ROA-7.00% Target Price92.67 Perf Year61.77%
Cash/sh2.30 P/C40.54 EPS next 5Y10.33% ROE-27.10% 52W Range57.01 - 96.58 Perf YTD29.42%
Dividend- P/FCF61.54 EPS past 5Y-33.10% ROI-7.70% 52W High-3.35% Beta1.14
Dividend %- Quick Ratio0.90 Sales past 5Y14.50% Gross Margin51.30% 52W Low63.73% ATR2.35
Employees5062 Current Ratio1.10 Sales Q/Q87.40% Oper. Margin19.30% RSI (14)56.73 Volatility2.09% 2.25%
OptionableYes Debt/Eq1.84 EPS Q/Q93.20% Profit Margin-25.10% Rel Volume0.52 Prev Close95.11
ShortableYes LT Debt/Eq1.77 EarningsApr 30 BMO Payout- Avg Volume3.11M Price93.34
Recom2.00 SMA201.87% SMA506.16% SMA20026.79% Volume1,618,654 Change-1.86%
Apr-16-15Reiterated Piper Jaffray Overweight $102 → $110
Apr-13-15Reiterated Deutsche Bank Buy $91 → $96
Mar-03-15Reiterated RBC Capital Mkts Outperform $80 → $98
Feb-02-15Reiterated CRT Capital Fair Value $73 → $80
Jan-30-15Reiterated Deutsche Bank Buy $81 → $91
Sep-02-14Initiated RBC Capital Mkts Outperform $80
Aug-01-14Reiterated Stifel Buy $75 → $84
Jun-27-14Initiated Canaccord Genuity Buy $83
Apr-30-14Initiated National Alliance Securities Buy $76
Mar-04-14Reiterated FBR Capital Mkt Perform $52 → $82
Mar-03-14Reiterated UBS Buy $75 → $90
Nov-06-13Upgrade Needham Underperform → Hold
Nov-06-13Reiterated Stifel Buy $40 → $60
Oct-30-13Initiated FBR Capital Mkt Perform $40
Sep-20-13Reiterated UBS Buy $43 → $50
Jun-21-13Resumed Oppenheimer Perform
Jun-06-13Reiterated UBS Buy $39 → $41
Jun-06-13Reiterated Stifel Buy $36 → $40
Jun-06-13Downgrade Cantor Fitzgerald Hold → Sell $36 → $30
May-13-13Reiterated Stifel Buy $42 → $36
Apr-13-15 05:17PM  Autohome, Other Foreign Stock Leaders Seen Posting Big Q1 at Investor's Business Daily
Apr-10-15 04:10PM  Permian Investment Partners Has A Thing or Two To Teach You About Investing at Insider Monkey
11:41AM  Endo International plc (ENDP), BioMarin Pharmaceutical Inc. (BMRN): Visium Picks Returned 13% but Net Returns Were Only 5% Heres Why at Insider Monkey
10:18AM  Tiger Ratan Trumps Hedge Fund Industry in Q1; See How Nehal Chopras Stock Picks Performed at Insider Monkey
Apr-09-15 09:30AM  Billionaire John Griffins Five Picks That Killed the Market This Quarter at Insider Monkey
Apr-06-15 10:35AM  What's Next For The Thousands Of Angry Men Suing Over Testosterone? at Forbes
Apr-02-15 02:25PM  3 JPMorgan Bull Calls Hitting The Market
01:41PM  These 10 Pharma and Health Care Stocks Were the Best S&P 500 Performers Last Quarter at TheStreet
Apr-01-15 02:52PM  Drugmaker Valeant completes $11 billion purchase of Salix
12:35PM  Valeant closes $11B deal for Raleigh's Salix Pharmaceuticals at
Mar-31-15 04:45PM  BioDelivery Slumps, Diabetic Pain Gel Fails Phase III Study - Analyst Blog
Mar-30-15 12:25PM  Can Boston Scientific Keep Its Turnaround Gains Going? at 24/7 Wall St.
Mar-28-15 07:00AM  Hyperion Could Be Next Pharma Target With Orphan Drugs: Real M&A at Bloomberg
Mar-27-15 11:06AM  Point72 Reduces Its Stake in Valeant Pharmaceuticals
Mar-23-15 03:11PM  Two Future Leaders of Specialty Pharma at
07:00AM  Actavis' Wide-Moat Transformation Offers Shareholder Rewards at Morningstar
12:12AM  [$$] Proceedings: News Digest at The Wall Street Journal
Mar-22-15 07:13PM  Proceedings: News Digest at The Wall Street Journal
Mar-19-15 01:35PM  Salix execs including two that resigned to receive $78M in golden parachutes at
Mar-18-15 05:10PM  Valeant (VRX) Prices Shares to Finance Salix Acquisition - Analyst Blog
09:30AM  The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Salix Pharmaceuticals, Endo International and Allergan - Press Releases
Mar-17-15 07:35PM  Endo Finance Co. -- Moody's confirms Endo's Ba3 ratings; outlook stable at Moody's
05:44PM  Valeant (VRX) Raises Salix Offer, Endo Withdraws Proposal - Analyst Blog
04:50PM  Investors in health-care stocks get rich as M&A booms at MarketWatch
12:09PM  Valeant Bonds Trade Higher, Despite Skepticism at
10:46AM  Valeant Bumps Its Offer to $173 to Seal the Salix Deal
05:55AM  For health-care stocks, buy what executives are buying at MarketWatch
01:08AM  PRESS DIGEST - Wall Street Journal - March 17 Reuters
Mar-16-15 11:12PM  Valeant Wins Battle for Salix Pharmaceuticals at The Wall Street Journal
07:41PM  Valeant Wins Salix After Raising Offer at The Wall Street Journal
06:03PM  Endo May Hunt Smaller Prey After Losing Out on Salix: Real M&A at Bloomberg
05:46PM  After-hours buzz: Jumei, American Air & more at CNBC
05:05PM  The Salix-Endo Proposal: Basics of the Transaction
05:00PM  Stocks End Higher Ahead of Fed Meeting
03:07PM  Why Valeant Had to Increase Salix Bidand Endo Had to Walk Away at
03:00PM  Dealpolitik: Valeant Sprints to Avoid a Marathon for Salix at The Wall Street Journal
02:29PM  Raised offer from Valeant knocks Endo out of Salix race at Financial Times
01:56PM  Valeant Pharma (VRX) Increases Bid for Salix (SLXP) to $173/share - Stocks in the News
01:40PM  Stocks Hold Near Day's Highs; Medical Issues Gain at Investor's Business Daily
01:16PM  Skadden Wins, and Also Loses, as Valeant Nabs Salix in Bidding War at The Wall Street Journal
01:06PM  Valeant/Salix: resistance is futile at Financial Times
01:05PM  What Investors Need to Know about Endo International
01:04PM  Watchman device approval boosts Boston Scientific at Financial Times
12:44PM  Valeant trumps Endo with $10.96 billion bid for Salix Pharma Reuters
12:09PM  Stocks Near Session Highs; Tesla Up On Musk Tweet at Investor's Business Daily
12:00PM  Valeant ups Salix bid to $11.11B and Endo ends quest
12:00PM  Stocks Higher Ahead of Fed Meeting
11:53AM  Dow adds 200 points amid dollar, oil slide; transports up 1.5% at CNBC
11:00AM  Valeant Pharmaceuticals Poised To Win Bidding War For Salix With $173 A Share Cash Deal at Forbes
10:43AM  Endo Drops Salix Bid On Raised Valeant Offer at Investor's Business Daily
10:36AM  Stocks Post Solid Gains At Open; Valeant Gets Salix, Endo Cedes at Investor's Business Daily
10:30AM  Bidding war for Salix shows confidence in its lead drug at
10:19AM  Valeant boosts bid for Salix; Endo drops out at
10:00AM  Valeant wins battle for Salix Pharmaceuticals at MarketWatch
09:57AM  Valeant ups Salix bid to about $11.11B; Endo withdraws offer
09:52AM  Salix agrees to Valeant's new offer; Endo withdraws its offer at
09:43AM  Endo pulls offer for Salix after Valeant ups bid at MarketWatch
09:36AM  Endo withdraws offer for Salix
09:31AM  Endo Withdraws Proposal For Salix at noodls
09:23AM  Endo Withdraws Proposal For Salix PR Newswire
09:23AM  Endo Withdraws Proposal For Salix CNW Group
09:11AM  Morning Movers: DuPont Tumbles on Merrill Lynch Downgrade; Valeant Gains on Higher Salix Bid at
08:13AM  Valeant raises offer for Salix Pharma to $173 per share Reuters
07:53AM  Endo Pharmaceuticals Announces the Launch of NATESTO (testosterone nasal gel), the First and Only Nasal Gel for Testosterone Replacement Therapy at noodls
07:30AM  Endo Pharmaceuticals Announces the Launch of NATESTO (testosterone nasal gel), the First and Only Nasal Gel for Testosterone Replacement Therapy PR Newswire
07:30AM  Endo Pharmaceuticals Announces the Launch of NATESTO (testosterone nasal gel), the First and Only Nasal Gel for Testosterone Replacement Therapy CNW Group
Mar-15-15 06:05PM  Endo claims it could close Salix deal swiftly - email
Mar-13-15 10:00PM  Valeant Mulls Higher Salix Bid, But Don't Expect $170 at Investor's Business Daily
08:07PM  Valeant plans to raise offer for Salix close to $170/shr -source Reuters
07:06PM  Important Indications: The Salix Situation Is Competitive
06:59PM  Valeant aims to sweeten $14.5bn Salix bid at Financial Times
04:05PM  Teachers fund exits position in Shire
03:17PM  Valeant deal survives Endo surprise Reuters
03:06PM  The Next Steps in the Salix-Endo Proposal
03:00PM  When Salix goes, it will mark the end of an era in the Triangle at
11:26AM  Valeant won't overpay for Salix: Bill Ackman at CNBC
11:10AM  Will BioDelivery Sciences (BDSI) Impress this Earnings? - Analyst Blog
10:10AM  Ackman Says Buying Salix at $170 Is a Mistake at The Wall Street Journal
09:54AM  Ackman says buying Salix at $170 is a mistake at MarketWatch
07:16AM  Yield-hungry investors clamour for debt at Financial Times
06:15AM  Endo Topped Valeants Bid for Salix Pharmaceuticals
01:21AM  PRESS DIGEST - Wall Street Journal - March 13
01:20AM  Heres How to Size Up Rival Bids for Salix at The Wall Street Journal
Mar-12-15 07:22PM  Here's How to Size Up Rival Bids for Salix at The Wall Street Journal
06:06PM  What Investors Shoud Know about Salix Pharmaceuticals
05:20PM  Salix Up on Endo Proposal Outstripping Valeant Offer - Analyst Blog
04:33PM  Dealpolitik: Three Reasons Why Valeant Should Move Quickly on Salix at The Wall Street Journal
03:54PM  Why Valeant Is Expected to Prevail in the War for Salix at The Wall Street Journal
03:10PM  When Salix goes, Raleigh jobs are at risk but also a silver lining at
03:02PM  Despite Uncertainty, Valeant's Huge Bond Sale Proceeds at
01:54PM  Why Valeant, Not Endo, Could Still Win The War For Salix
01:28PM  William Blair Says Cash Is King In Salix Bidding War
01:10PM  Wall Street says Valeant likely to win bidding war for Salix at MarketWatch
01:00PM  Valeant vs Endo: Who Will Win the Fight for Salix at
11:47AM  Endo Finance Co. -- Moody's reviews Endo's ratings for downgrade at Moody's
10:15AM  Pharma ETFs to Soar No Matter Who Wins Salix - ETF News And Commentary
10:10AM  Stock Market News for March 12, 2015 - Market News
09:38AM  Faber Report: Battle over Salix
09:13AM  ENDO INTERNATIONAL PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
02:34AM  PRESS DIGEST- New York Times business news - March 12 Reuters
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment provides various branded prescription products, including Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto to treat and manage pain and conditions in urology, endocrinology, and oncology. The U.S. Generic Pharmaceuticals segment offers products in the pain management, urology, CNS disorders, immunosuppression, oncology, women's health, hypertension, generic lidocaine patch, and other markets. The Devices segment provides various medical devices comprising AMS 800 artificial urinary sphincters, AMS 700 MS series, Monarc subfascial hammock products, Elevate anterior and posterior pelvic floor repair systems, and GreenLight XPS laser systems in the areas of men's and women's pelvic health. The International Pharmaceuticals segment offers Dexedrine, Tridural, Metadol, Trandate, Pennsaid, and Plan B products in therapeutic areas, including attention deficit hyperactivity disorder, pain, urology, and allergy. It sells its branded pharmaceuticals and generics directly to large pharmacy chains; and through wholesale drug distributors to pharmacies, hospitals, governmental agencies, and physicians. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.